Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT04690374
- Status
- Recruiting
Conditions
- Desmoplastic Small Round Cell Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study is a patient registry of people with Desmoplastic Small Round Cell Tumor (DSRCT). A patient registry is a collection of health information about a group of people, and it is usually focused on a specific diagnosis or disease. The purpose of this registry is to create a database- a collection of information-or better understanding DSRCT. Researchers will use the information from this database to learn more about DSRCT and for current and future research on DSRCT.
Key Dates
- First listed
- Dec 30, 2020
- Start date
- Dec 22, 2020
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 250 participants (estimated)
Arms
- Arm: Desmoplastic small round cell tumor (DSRCT)Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT
Primary Outcome Measure
Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor [ Time Frame: 7 years ]
Central Contacts
- Emily Slotkin, MD1-833-675-5437
- Shakeel Modak, MD1-833-675-5437
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Emily Slotkin, MD 833-675-5437 Shakeel Modak, MD 1-833-675-5437 Emily Slotkin, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
Related Studies
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Atlanta, Georgia
- Lurbinectedin in FET-Fused TumorsPHASE1/PHASE2 · Recruiting · Children's Hospital of Philadelphia · Los Angeles, California
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsPHASE1/PHASE2 · Recruiting · University of Florida · Gainesville, Florida